Friday, March 25, 2022

< + > Moderna Stock Plunges Despite 'Vaccine Day' Touting 31 New Shots And $21 Billion In Sales—Here's Why

One analyst blasted Moderna's flu vaccine results as a "non-starter" clinically, while others said investors are still too focused on Covid.

at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

< + > What's behind EHR-induced clinician burnout? And how to solve it?

When evaluating electronic health record systems to minimize documentation burden, usability is always the big challenge, says one informati...